Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $89.3 million.

  • Foghorn Therapeutics' Cash & Equivalents rose 5488.4% to $89.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.3 million, marking a year-over-year increase of 5488.4%. This contributed to the annual value of $55.5 million for FY2024, which is 3097.24% down from last year.
  • Per Foghorn Therapeutics' latest filing, its Cash & Equivalents stood at $89.3 million for Q3 2025, which was up 5488.4% from $72.6 million recorded in Q2 2025.
  • Foghorn Therapeutics' Cash & Equivalents' 5-year high stood at $213.6 million during Q1 2022, with a 5-year trough of $50.6 million in Q1 2023.
  • Moreover, its 5-year median value for Cash & Equivalents was $70.3 million (2023), whereas its average is $83.1 million.
  • In the last 5 years, Foghorn Therapeutics' Cash & Equivalents soared by 182997.39% in 2021 and then crashed by 7629.67% in 2023.
  • Over the past 5 years, Foghorn Therapeutics' Cash & Equivalents (Quarter) stood at $101.1 million in 2021, then tumbled by 48.37% to $52.2 million in 2022, then skyrocketed by 53.86% to $80.3 million in 2023, then crashed by 30.97% to $55.5 million in 2024, then surged by 61.1% to $89.3 million in 2025.
  • Its Cash & Equivalents stands at $89.3 million for Q3 2025, versus $72.6 million for Q2 2025 and $61.0 million for Q1 2025.